# Phase II Study of Digitoxin to Treat Cystic Fibrosis

> **NCT00782288** · PHASE2 · COMPLETED · sponsor: **National Jewish Health** · enrollment: 24 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** digitoxin
- **DRUG:** digitoxin
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00782288
- **Lead sponsor:** National Jewish Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782288, "Phase II Study of Digitoxin to Treat Cystic Fibrosis". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00782288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*